DAAs lower risk for death among patients with HCV, regardless of cirrhosis

Treatment with direct-acting antivirals was associated with decreased mortality among a sample of more than 50,000 Medicare beneficiaries with hepatitis C virus, regardless of the presence of cirrhosis, according to data published in JAMA Network Open.Yamini Kalidindi, MHA, an associate at the Moran Company, and colleagues noted that HCV is the most common bloodborne illness in the United States, and that evidence of the cost-effectiveness of DAA treatment is lacking.“Previous simulations used extended lives as a key outcome to indicate that the benefits associated with DAA treatmentRead More

Share on facebook
Share on twitter
Share on linkedin